A new scientific publication recently came out in the Biological Psychiatry journal announcing that results of an ongoing Phase 2 study of LSD-assisted therapy for patients suffering from anxiety with or without life-threatening illnesses show encouraging drug effects.

The trial was led by the University Hospital Basel (UHB), a research collaborator of biotech psychedelics company MindMed (NASDAQ: MNMD) currently developing proprietary LSD analogue MM-120 for the treatment of Generalized Anxiety Disorder (GAD). 

The published results state that “LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms up to 16 weeks,” which according to the company is consistent with the treatment’s previously reported positive results for anxiety disorders.

"These results …

Full story available on Benzinga.com